Table A1. Antimicrobial drug susceptibility profiles of CV isolates compared with Mycobacterium chelonae, M. massiliense, and M. abscessus isolates*.

Antimicrobial drug	M. abscessus, n = 41					M. massiliense, n = 5					M. chelonae, n = 58					CV, n = 25
	Range	S, %	I, %	R, %		Range	S, %	I, %	R, %		Range	S, %	I , %	R, %		Range	S, %	I, %	R, %
Amikacin	8−32	73.2	26.8	0.0		8−32	60.0	40.0	0.0		8−>256	32.8	51.7	15.5		8−32	92.0	8.0	0.0
Cefoxitin	16−64	9.8	90.2	0.0		16−32	40.0	60.0	0.0		64−> 512	0.0	1.7	98.3		16−64	12.0	88.0	0.0
Ciprofloxacin†	<0.25−>32	2.4	0.0	97.6		4−16	0.0	0.0	100.0		1−>32	8.6	17.2	74.2		<0.25−8	60.0	20.0	20.0
Clarithromycin	<0.12−4	97.6	2.4	0.0		<0.12	100.0	0.0	0.0		<0.12−>64	98.3	0.0	2.4		<0.12−1	100.0	0.0	0.0
Gatifloxacin‡	<0.5−>16	2.4	14.6	83.0		4−16	0.0	20.0	80.0		1−>16	31.0	44.8	24.2		<0.5−4§	80.0	20.0	0.0
Imipenem	1−32	14.6	53.6	31.8		8	0.0	100.0	0.0		<0.5−64	10.3	34.5	55.2		1−64	16.0	44.0	40.0
Linezolid	4−32	43.9	36.6	19.5		8−16	20.0	60.0	20.0		<0.1−32	81.0	13.8	5.2		1−32	72.0	24.0	4.0
Minocycline	8−64	0.0	4.9	95.1		64	0.0	0.0	100.0		<0.5−>64	15.5	3.5	81.0		<0.5−16¶	90.9	9.1	0.0
Tobramycin	4−32	2.4	22.0	75.6		8−32	0.0	0.0	100.0		1−>128	98.3	0.0	1.7		4−16#	62.5	29.2	8.3
Trimethoprim/ sulfamethoxazole	4/76−>16/304	0.0	–	100.0		>16/304	0.0	–	100.0		<0.5/9.5−>16/304	5.2	–	94.8		1/9−>16/304	8.0	–	92.0

*CV, M. chelonae variant; S, susceptible; I, intermediate; R, resistant; –, not applicable. One CV isolate did not grow on solid media.
†Read at 3 days
‡No CLSI breakpoint recommendation has been proposed for gatifloxacin. Manufacturer recommendation of 4 used as the intermediate breakpoint.
§10 isolates tested.
¶22 isolates tested.
#24 isolates tested.